C2N Diagnostics said Anthem Blue Cross/Blue Shield members will receive insurance coverage for the PrecivityAD2 blood test starting October 1, 2026, making it the first such covered policy in the U.S. The coverage expands patient access to the blood-based Alzheimer’s diagnostic, supporting commercial adoption of the test.
This is more important as a reimbursement precedent than as an immediate revenue event. The economic value in Alzheimer’s diagnostics usually accrues to whoever can become the default workflow inside primary care and neurology, so a first payer acceptance lowers the perceived adoption risk for the whole category even if this specific contract is small near term. The first-order winner is the assay owner, but the second-order winner may be the broader screening ecosystem if other commercial plans follow the same policy language. The bigger downstream beneficiary is likely the therapy layer, not the diagnostic layer. Easier blood-based triage expands the pool of patients who can be moved into confirmed treatment pathways, which helps LLY and BIIB more than it helps any single test vendor if payer norms normalize blood-first algorithms. That also creates a subtle loser set: amyloid PET and other expensive confirmatory workflows face slower unit growth if clinicians accept blood testing as the front door rather than the exception. The main risk is timing. Coverage starting in 2026 means there is little immediate P&L impact, and one payer does not establish a national standard; if utilization is limited to specialty centers or if confirmatory testing remains high, the commercial upside can stall. The thesis is falsified if the next 2-4 payer decisions do not replicate this policy, or if later claims data show that the blood test is merely substituting for PET/CSF without expanding the addressable treated population.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
